An interventional study of Cardiac coherence in Long COVID, sponsored by Centre Hospitalier Universitaire de la Réunion. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Centre Hospitalier Universitaire de la Réunion · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Post-Acute COVID-19 Syndrome with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · France.
Among the 16 studies in Post-Acute COVID-19 Syndrome with a site in France, this one is one of 3 that started in 2025, is one of 6 with no phase, and was the 10th registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →5 of the 16 studies in Post-Acute COVID-19 Syndrome with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Central Hospital, Nancy, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 200 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 131 across the 6 interventional studies, 501 across the 10 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 141 studies on the registry; 37 are open to participants now.
Centre Hospitalier Universitaire de la Réunion has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851859Centre Hospitalier Universitaire de la RéunionEvaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Post-Acute COVID-19 Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.
The Reunion Island is a French overseas department located in the Indian Ocean accounting more than 860,000 inhabitants. It has recorded since March 11, 2020, nearly 491,825 cases of COVID-19 and 961 deaths of hospitalized patients. Reunion's population is multi-ethnic and younger than the metropolitan France's one. It also has a higher prevalence of obesity and type 2 diabetes, two serious form factors of COVID-19. This specific context makes this island a particular study site for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Long COVID.
In addition, some studies have confirmed the involvement of the autonomic nervous system (ANS) in the symptomatology of Long COVID and demonstrated that patients with a Long COVID present a dysfunction of their ANS which is objectified by a reduced Heart Rate Variability (HRV). The regulation of heart rate by the ANS is strongly favored by respiration. A regular slow and deep breathing training helps to adjust the baroreflex, which connect heart rate, breathing and blood pressure. The result of this training is an induced state called "cardiac coherence" (CC).
The investigator therefore hypothesize that respiratory training to CC could "re-educate" the ANS and durably improve the symptomatology of patients with Long COVID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The " intervention " group will benefit from a complementary respiratory training to CC during 6 months in addition to the usual care procedure.
Other: Cardiac coherence
The " control " group will follow a usual care procedure in the event of Long COVID
Use of Cardiac coherence (complementary respiratory training) during 6 month
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the reduction in the symptomatology of patients with Long COVID.
mean score on the Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome
Time frame: 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of overall symptoms over time
Long COVID Symptom Tool (ST) scale Score 0 to 53 / Higher score mean worse outcome
Time frame: T0, 1 month, 2 months, 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : fatigue
The 11-item Chalder Fatigue Scale (CFS-11) score 0 to 11 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : dyspnoea
Modified Medical Research Council (MMRC) dyspnoea scale score 0 to 5 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : Anxiety and Depression
Hospital Anxiety and Depression scale (HADS) Score 0 to 42 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : cognitive disorders
Montreal Cognitive Assessment (MoCA) Score 0 to 30 / Higher score mean better outcome
Time frame: 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : Post Traumatic Stress Disorder
Posttraumatic Stress Disorder Checklist for Diagnostic and statistical manual of mental disorders, version 5 (PCL-5) Score 0 to 80 / Higher score mean worse outcome
Time frame: 3 months, 6 months
Evaluation of the effectiveness of a respiratory training to CC on the impact of the disease on daily life
Long COVID Impact Tool (IT) scale Score 0 to 60 / Higher score mean worse outcome
Time frame: T0, 1 month, 2 months, 3 months, 6 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 233 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 18 months is above that.
Counting every sponsor, half of 244 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Centre Hospitalier Universitaire de la Réunion →